In-vitro diagnostics. Point-of-care tests. Molecular diagnostics. Clinical lab tools. If your product touches the diagnostic pathway, we know how to market it.
Diagnostics companies face a layered commercial challenge that most agencies aren't built to handle. Your buyers are technical. Your regulatory environment dictates what you can claim and when. And your channels — lab systems, hospital networks, direct-to-consumer, international distributors — each operate with entirely different decision-making structures. Meanwhile, your investors expect commercial clarity at exactly the moment your team is deep in assay development. Most agencies see "diagnostics" and default to the same playbook they use for pharma or medical devices. That's not this.
We know the IVD space: lateral flow, ELISA, PCR and qPCR, NGS-based diagnostics, point-of-care platforms, companion diagnostics, LDTs.
We know the trade press: 360Dx, GenomeWeb, FierceBiotech, Clinical Lab Products, MedTech Dive.
We know the conferences where your buyers and investors gather: AACC, ADLM, POCT International.
We know which investors are active in this space and what they want to hear.
We understand that diagnostic marketing copy lives inside a regulatory framework: CE/IVDR, FDA, CLIA waiver claims, LDT considerations.
We know what you can and can't say, and we build that into the work from the start.
Commercialization strategy and investor-ready messaging. The pitch that explains your assay's clinical utility without dumbing it down. VC and partner targeting. The foundational assets, website, technology brief, and pitch deck that tell investors and partners you're commercially ready.
Competitive positioning and differentiation. Sales team support: account research, lead generation, campaign support for lab system evaluators, hospital formulary committees, and distributor partners. KOL identification and engagement. Trade show strategy and execution. Market intelligence that gives your commercial team a real advantage. Content that establishes credibility with clinical buyers: white papers, application notes, clinical evidence summaries, written by PhD-level scientists. Digital presence and discoverability strategies that account for how your buyers and investors research the market today.
Specialized execution that sits outside your team's bandwidth: scientific symposia produced end to end, market intelligence reports, KOL programs, technical content, product launches in new indications. We execute faster and with deeper domain expertise than a generalist agency. We integrate cleanly alongside your existing team.
Some diagnostics companies sell directly to consumers through retail, DTC, and digital channels. If your buyers are end-users rather than lab directors or clinical buyers, the marketing strategy is different—different channels, different content, different language.
Your science is ready.
Two paths in. Pick the one that fits.
